Bold Therapeutics Inc.: federal grants and contributions: 16 agreements; $3.0M value; 2 departments; 7 programs.
Assay record ASY-CA-1HP6C850F2 · Cite as: Assay Systems, “Bold Therapeutics Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/bold-therapeutics-inc/
BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of patients with cancer and viral infections, including COVID-19. BOLD-100 has previously been shown to have antiviral activity against SARS-CoV-2 in an vitro model. This project focuses on completing the preclinical data package, preparing for clinical trial in COVID-19, and supporting manufacturing.
The project goal is to build and validate a screening platform for identification of metal-based anticancer therapeutics with unique and promising characteristics for subsequent development.
BOLD-100 is a novel therapeutic that synergies with existing drugs to treat cancer. Project investigates the underlying mechanism behind BOLD-100, leading to new treatment combinations in additional cancer indications.
This project will investigate the mode of action of neuroprotective activity of BOLD-100, the Firm's lead metallotherapeutic candidate for cancer therapy.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
This position will support the Company's oncology research efforts by working with the Director of Preclinical Development to offer bioinformatics expertise to analyze large and complex datasets to advance the understanding of the company’s lead asset, BOLD-100. The employee will work on analyzing large and complex datasets using bioinformatics tools, including cell line screens; perform analyses and research; and draft reports on the analyzed data.
The business development assistant will support the corporate team in the areas of business development, internal finance, investor communications and accounting.
The Firm is developing a pipeline of metal-based compounds as potential anti-cancer therapeutics. The youth hire will support bioactivity screening of novel compounds in vitro.
The project will support development of intellectual property capacity within the firm.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
This Project will support the Firm's clinical and preclinical research efforts.
The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Research and Development (R&D) partnerships between the Recipient and foreign organizations in order to support R&D on the Recipient’s technology and advance its commercialization.
The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Research and Development (R&D) partnerships between the Recipient and foreign organizations in order to support R&D on the Recipient’s technology and advance its commercialization.
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
The purpose of the Canadian International Innovation Program (CIIP) grant agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.